- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00475904
A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)
July 25, 2011 updated by: EpiCept Corporation
A Phase II, Double-Blind, Randomized, Placebo-Controlled Non-inferiority Trial of EpiCept™ NP-1 Topical Cream (2% Ketamine / 4% Amitriptyline) vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)
The purpose of this study is to compare EpiCept™ NP-1 Topical Cream (2% ketamine / 4% amitriptyline) vs. Oral Gabapentin in the treatment of Postherpetic Neuralgia (PHN)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a phase II, multicenter, double-blind, randomized, placebo-controlled, parallel group study of NP-1 and oral gabapentin in approximately 500 patients with PHN. Adult patients with pain resulting from PHN and meeting all other eligibility requirements will be screened for 7 days to determine their average daily pain intensity.
Qualifying patients will be randomized on a 2:2:1 basis to NP-1, oral gabapentin, or placebo.
The treatment period will be 4-Weeks.
Study Type
Interventional
Enrollment (Actual)
360
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
New Delhi, India, 110016
- Multiple Centers
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult patients with pain for ≥ 3 months following onset of a herpes zoster rash
Exclusion Criteria:
- Clinically significant intercurrent illness (e.g., endocrine, cardiac, hepatic, renal, neurologic, hematologic, skeletal) that the investigator determines could interfere with the efficacy or safety assessments.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: amitriptyline 4% ketamine 2% cream, placebo capsules
Np-1 cream and placebo gabapentin
|
ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks
|
Active Comparator: gabapentin capsules, placebo cream
gabapentin caps and placebo cream
|
1800mg/day capsules for 4 weeks
Other Names:
|
Placebo Comparator: placebo cream and capsules
|
placebo cream and caps
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Pain Scores Comparing NP-1 Cream vs. Placebo Cream for Treatment of the Pain of Post Herpetic Neuralgia(PHN)From Baseline to 28 Days.
Time Frame: baseline and 28 days
|
Difference in pain scores between NP-1 cream vs. placebo cream for the treatment of the pain of PHN.
Baseline pain scores were compared to the pain scores after 28 days of treatment.
Pain scores were rated on a 11 point numerical rating scale (0-10) where 0 was no pain and 10 was worst possible pain.
|
baseline and 28 days
|
Change in Pain Intensity From Baseline to 28 Days of Treatment, Comparison Between NP-1 Topical Cream and Oral Gabapentin
Time Frame: baseline to 28 Days
|
Change in pain intensity scores between NP-1 cream vs. oral gabapentin for the treatment of the pain of PHN.
Baseline pain scores were compared to the pain scores after 28 days of treatment.
Pain scores were rated on a 11 point numerical rating scale (0-10) where 0 was no pain and 10 was worst possible pain.
|
baseline to 28 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2007
Primary Completion (Actual)
June 1, 2008
Study Completion (Actual)
June 1, 2008
Study Registration Dates
First Submitted
May 17, 2007
First Submitted That Met QC Criteria
May 18, 2007
First Posted (Estimate)
May 21, 2007
Study Record Updates
Last Update Posted (Estimate)
July 27, 2011
Last Update Submitted That Met QC Criteria
July 25, 2011
Last Verified
July 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Neuralgia
- Neuralgia, Postherpetic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Anti-Anxiety Agents
- Anticonvulsants
- Antimanic Agents
- Gabapentin
Other Study ID Numbers
- EPC2007-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathy
-
Arash Asher, MDVoxxLifeRecruitingNeuropathy | Chemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
Henry Ford Health SystemOctapharma USA, Inc.RecruitingSmall Fiber Neuropathy | Autoimmune Small Fiber Neuropathy | Inflammatory Polyneuropathy | Immune-Mediated NeuropathyUnited States
-
Nihon Pharmaceutical Co., LtdCompletedMultifocal Motor NeuropathyJapan
-
University of AarhusCompletedMultifocal Motor NeuropathyDenmark
-
Beth Israel Deaconess Medical CenterPhoenix Neurological Associates, LTDCompletedSmall Fiber Neuropathy | Idiopathic Peripheral NeuropathyUnited States
-
Tanta UniversityCompletedDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Painful Diabetic Neuropathy | Autonomic Neuropathy | Diabetic Polyneuropathy | Small Fiber NeuropathyEgypt
-
Yung-Tsan WuCompleted
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Sorlandet Hospital HFOslo University Hospital; University Hospital of North Norway; University Hospital...Not yet recruitingSmall Fiber Neuropathy | Sensory Neuropathy
-
Tri-Service General HospitalCompleted
Clinical Trials on EpiCept-NP-1 Cream
-
EpiCept CorporationCompletedNeuralgia | Diabetic Peripheral NeuropathyIndia
-
Philip Morris Products S.A.Completed
-
Novita Pharmaceuticals, Inc.RecruitingAdvanced or Metastatic Solid Tumor MalignanciesUnited States
-
Gary MorrowNational Cancer Institute (NCI)CompletedPain | Unspecified Adult Solid Tumor, Protocol Specific | Neurotoxicity | Peripheral NeuropathyUnited States
-
GlaxoSmithKlineCompletedDermatitis, AtopicUnited States, Canada, Japan
-
Dermavant Sciences GmbHCompletedAtopic DermatitisUnited States, Canada
-
Dermavant Sciences GmbHCompletedAtopic DermatitisUnited States, Canada
-
GlaxoSmithKlineCompletedPsoriasisUnited States, Canada, Japan
-
GlaxoSmithKlinePPD; ERT: Clinical Trial Technology Solutions; Q2 SolutionsWithdrawn
-
University of ParmaCompletedInflammatory Response | Endotoxemia | Oxidative Stress | Glucose, High BloodItaly